Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy

Abstract Background Published literature suggests that early treatment with natalizumab (“escalation strategy”) is more effective than switch within the same class of immunomodulators (interferons/glatiramer acetate, “switching strategy”) in relapsing-remitting multiple sclerosis (RRMS) patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Gianluca Furneri, Laura Santoni, Chiara Ricella, Luca Prosperini
Formato: Artículo
Lenguaje:English
Publicado: BMC 2019-06-01
Colección:BMC Health Services Research
Materias:
Multiple sclerosis
Natalizumab
Glatiramer acetate
Interferon-beta
Cost-effectiveness
Markov
Acceso en línea:http://link.springer.com/article/10.1186/s12913-019-4264-1

Internet

http://link.springer.com/article/10.1186/s12913-019-4264-1

Ejemplares similares